189 related articles for article (PubMed ID: 22238365)
1. (212)Pb-radioimmunotherapy induces G(2) cell-cycle arrest and delays DNA damage repair in tumor xenografts in a model for disseminated intraperitoneal disease.
Yong KJ; Milenic DE; Baidoo KE; Brechbiel MW
Mol Cancer Ther; 2012 Mar; 11(3):639-48. PubMed ID: 22238365
[TBL] [Abstract][Full Text] [Related]
2. Sensitization of tumor to ²¹²Pb radioimmunotherapy by gemcitabine involves initial abrogation of G2 arrest and blocked DNA damage repair by interference with Rad51.
Yong KJ; Milenic DE; Baidoo KE; Brechbiel MW
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(4):1119-26. PubMed ID: 23200172
[TBL] [Abstract][Full Text] [Related]
3. Gene expression profiling upon (212) Pb-TCMC-trastuzumab treatment in the LS-174T i.p. xenograft model.
Yong KJ; Milenic DE; Baidoo KE; Kim YS; Brechbiel MW
Cancer Med; 2013 Oct; 2(5):646-53. PubMed ID: 24403230
[TBL] [Abstract][Full Text] [Related]
4. 212Pb-radioimmunotherapy potentiates paclitaxel-induced cell killing efficacy by perturbing the mitotic spindle checkpoint.
Yong KJ; Milenic DE; Baidoo KE; Brechbiel MW
Br J Cancer; 2013 May; 108(10):2013-20. PubMed ID: 23632482
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of Cell Killing Response from Low Linear Energy Transfer (LET) Radiation Originating from (177)Lu Radioimmunotherapy Targeting Disseminated Intraperitoneal Tumor Xenografts.
Yong KJ; Milenic DE; Baidoo KE; Brechbiel MW
Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27196891
[TBL] [Abstract][Full Text] [Related]
6. Impact of α-targeted radiation therapy on gene expression in a pre-clinical model for disseminated peritoneal disease when combined with paclitaxel.
Yong KJ; Milenic DE; Baidoo KE; Brechbiel MW
PLoS One; 2014; 9(9):e108511. PubMed ID: 25268703
[TBL] [Abstract][Full Text] [Related]
7. Potentiation of high-LET radiation by gemcitabine: targeting HER2 with trastuzumab to treat disseminated peritoneal disease.
Milenic DE; Garmestani K; Brady ED; Albert PS; Abdulla A; Flynn J; Brechbiel MW
Clin Cancer Res; 2007 Mar; 13(6):1926-35. PubMed ID: 17363549
[TBL] [Abstract][Full Text] [Related]
8. Dose escalation and dosimetry of first-in-human α radioimmunotherapy with 212Pb-TCMC-trastuzumab.
Meredith R; Torgue J; Shen S; Fisher DR; Banaga E; Bunch P; Morgan D; Fan J; Straughn JM
J Nucl Med; 2014 Oct; 55(10):1636-42. PubMed ID: 25157044
[TBL] [Abstract][Full Text] [Related]
9. Safety and Outcome Measures of First-in-Human Intraperitoneal α Radioimmunotherapy With 212Pb-TCMC-Trastuzumab.
Meredith RF; Torgue JJ; Rozgaja TA; Banaga EP; Bunch PW; Alvarez RD; Straughn JM; Dobelbower MC; Lowy AM
Am J Clin Oncol; 2018 Jul; 41(7):716-721. PubMed ID: 27906723
[TBL] [Abstract][Full Text] [Related]
10. Exploration of a F(ab')
Milenic DE; Kim YS; Baidoo KE; Wong KJ; Barkley R; Delgado J; Brechbiel MW
Cancer Biother Radiopharm; 2018 Jun; 33(5):182-193. PubMed ID: 29916748
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of cetuximab as a candidate for targeted α-particle radiation therapy of HER1-positive disseminated intraperitoneal disease.
Milenic DE; Baidoo KE; Kim YS; Brechbiel MW
MAbs; 2015; 7(1):255-64. PubMed ID: 25587678
[TBL] [Abstract][Full Text] [Related]
12. Cell Killing Mechanisms and Impact on Gene Expression by Gemcitabine and 212Pb-Trastuzumab Treatment in a Disseminated i.p. Tumor Model.
Yong KJ; Milenic DE; Baidoo KE; Brechbiel MW
PLoS One; 2016; 11(7):e0159904. PubMed ID: 27467592
[TBL] [Abstract][Full Text] [Related]
13. Targeting HER2: a report on the in vitro and in vivo pre-clinical data supporting trastuzumab as a radioimmunoconjugate for clinical trials.
Milenic DE; Wong KJ; Baidoo KE; Nayak TK; Regino CA; Garmestani K; Brechbiel MW
MAbs; 2010; 2(5):550-64. PubMed ID: 20716957
[TBL] [Abstract][Full Text] [Related]
14. Alpha-particle radioimmunotherapy of disseminated peritoneal disease using a (212)Pb-labeled radioimmunoconjugate targeting HER2.
Milenic DE; Garmestani K; Brady ED; Albert PS; Ma D; Abdulla A; Brechbiel MW
Cancer Biother Radiopharm; 2005 Oct; 20(5):557-68. PubMed ID: 16248771
[TBL] [Abstract][Full Text] [Related]
15. Pb-214/Bi-214-TCMC-Trastuzumab inhibited growth of ovarian cancer in preclinical mouse models.
Metebi A; Kauffman N; Xu L; Singh SK; Nayback C; Fan J; Johnson N; Diemer J; Grimm T; Zamiara M; Zinn KR
Front Chem; 2023; 11():1322773. PubMed ID: 38333550
[No Abstract] [Full Text] [Related]
16. CD46 targeted
Li J; Huang T; Hua J; Wang Q; Su Y; Chen P; Bidlingmaier S; Li A; Xie Z; Bidkar AP; Shen S; Shi W; Seo Y; Flavell RR; Gioeli D; Dreicer R; Li H; Liu B; He J
J Exp Clin Cancer Res; 2023 Mar; 42(1):61. PubMed ID: 36906664
[TBL] [Abstract][Full Text] [Related]
17. Multimodality therapy: potentiation of high linear energy transfer radiation with paclitaxel for the treatment of disseminated peritoneal disease.
Milenic DE; Garmestani K; Brady ED; Baidoo KE; Albert PS; Wong KJ; Flynn J; Brechbiel MW
Clin Cancer Res; 2008 Aug; 14(16):5108-15. PubMed ID: 18698028
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of platinum chemotherapy in combination with HER2-targeted α-particle radiation.
Milenic DE; Baidoo KE; Shih JH; Wong KJ; Brechbiel MW
Cancer Biother Radiopharm; 2013; 28(6):441-9. PubMed ID: 23758610
[TBL] [Abstract][Full Text] [Related]
19. Improved efficacy of alpha-particle-targeted radiation therapy: dual targeting of human epidermal growth factor receptor-2 and tumor-associated glycoprotein 72.
Milenic DE; Brady ED; Garmestani K; Albert PS; Abdulla A; Brechbiel MW
Cancer; 2010 Feb; 116(4 Suppl):1059-66. PubMed ID: 20127951
[TBL] [Abstract][Full Text] [Related]
20. α-Radioimmunotherapy with ²¹³Bi-anti-CD38 immunoconjugates is effective in a mouse model of human multiple myeloma.
Teiluf K; Seidl C; Blechert B; Gaertner FC; Gilbertz KP; Fernandez V; Bassermann F; Endell J; Boxhammer R; Leclair S; Vallon M; Aichler M; Feuchtinger A; Bruchertseifer F; Morgenstern A; Essler M
Oncotarget; 2015 Mar; 6(7):4692-703. PubMed ID: 25576914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
